As of the summer of 2013, Sanofi was in a race with Amgen and Pfizer to win approval for a drug that inhibits PCSK9 , a protein that slows the clearance of low-density lipoprotein (LDL) cholesterol - the form of cholesterol that leads to heart attacks.  Sanofi's drug was discovered by Regeneron and is called alirocumab .  An FDA warning in March 2014 about possible cognitive adverse effects of PCSK9 inhibition threw the competition into disarray, as the FDA asked companies to include neurocognitive testing into their Phase III clinical trials. 
Generic Biosimilars 2018 conveys recent developments in Generic drug marketing and production of generic drugs and contract manufacturing. A complete knowledge of a scientific discipline that described the effects of generic drug marketing and generic Pharma now explores the Scope of generic drug marketing in industry. Generic Biosimilars 2018 provides detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.